JP2024526191A5 - - Google Patents
Info
- Publication number
- JP2024526191A5 JP2024526191A5 JP2023579304A JP2023579304A JP2024526191A5 JP 2024526191 A5 JP2024526191 A5 JP 2024526191A5 JP 2023579304 A JP2023579304 A JP 2023579304A JP 2023579304 A JP2023579304 A JP 2023579304A JP 2024526191 A5 JP2024526191 A5 JP 2024526191A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- isotopolog
- tautomer
- stereoisomer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163215243P | 2021-06-25 | 2021-06-25 | |
| US63/215,243 | 2021-06-25 | ||
| PCT/US2022/034921 WO2022272074A1 (en) | 2021-06-25 | 2022-06-24 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024526191A JP2024526191A (ja) | 2024-07-17 |
| JP2024526191A5 true JP2024526191A5 (enExample) | 2025-06-30 |
| JP7904250B2 JP7904250B2 (ja) | 2026-08-12 |
Family
ID=84543920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023579304A Active JP7904250B2 (ja) | 2021-06-25 | 2022-06-24 | セレブロン結合化合物、その組成物及びそれによる治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240368118A1 (enExample) |
| EP (1) | EP4359407A4 (enExample) |
| JP (1) | JP7904250B2 (enExample) |
| KR (1) | KR20240026939A (enExample) |
| CN (1) | CN117561249A (enExample) |
| WO (1) | WO2022272074A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240146608A (ko) * | 2023-03-29 | 2024-10-08 | 주식회사 아이비스바이오 | 세레블론 결합 활성을 가지는 저분자 화합물 및 이의 용도 |
| KR20260041885A (ko) | 2023-07-25 | 2026-03-27 | 몬테 로사 테라퓨틱스 아게 | 표적화된 단백질 분해를 위한 치환된 피페리딘디온 |
| WO2026099466A1 (en) * | 2024-11-08 | 2026-05-15 | Monte Rosa Therapeutics Ag | Targeted protein degradation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6817962B2 (ja) * | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| IL319363A (en) * | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| WO2019023553A1 (en) | 2017-07-28 | 2019-01-31 | Arvinas, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR |
| BR112021011968A2 (pt) | 2018-12-19 | 2021-09-08 | Celgene Corporation | Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos |
| EP4031247A1 (en) | 2019-09-16 | 2022-07-27 | Novartis AG | Bifunctional degraders and their methods of use |
| IL299256A (en) | 2020-06-24 | 2023-02-01 | Celgene Corp | Cerebellum binding compounds, their compounds and methods of treatment with them |
-
2022
- 2022-06-24 KR KR1020237044476A patent/KR20240026939A/ko active Pending
- 2022-06-24 CN CN202280044021.6A patent/CN117561249A/zh active Pending
- 2022-06-24 US US18/573,723 patent/US20240368118A1/en active Pending
- 2022-06-24 EP EP22829394.0A patent/EP4359407A4/en active Pending
- 2022-06-24 JP JP2023579304A patent/JP7904250B2/ja active Active
- 2022-06-24 WO PCT/US2022/034921 patent/WO2022272074A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023533203A5 (enExample) | ||
| JP2023531709A5 (enExample) | ||
| JP2023531495A5 (enExample) | ||
| JP2022512482A5 (enExample) | ||
| JP7759877B2 (ja) | 治療用化合物 | |
| JP2022520448A5 (enExample) | ||
| JP2024520481A5 (enExample) | ||
| WO2021203768A1 (zh) | 嘧啶并二环类衍生物、其制备方法及其在医药上的应用 | |
| CN113365997A (zh) | 作为c-Met抑制剂的含嘧啶基团的三并环类化合物 | |
| JP2021535207A5 (enExample) | ||
| JP2019537559A5 (enExample) | ||
| WO2019134539A1 (zh) | 二氢吡唑酮并嘧啶类化合物及其制备方法和用途 | |
| JP2008509949A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2024516033A5 (enExample) | ||
| JP2020063289A5 (enExample) | ||
| JP2014514290A5 (enExample) | ||
| JP2014520108A5 (enExample) | ||
| JP2008513485A5 (enExample) | ||
| CA2617991A1 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | |
| CN115677664A (zh) | 作为parp7抑制剂的哒嗪酮类化合物 | |
| JP2007531766A5 (enExample) | ||
| JP2022529309A5 (enExample) | ||
| JP2020533319A5 (enExample) | ||
| JP2021520415A5 (enExample) |